Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate

The BLA and MAA acceptances represent significant milestones in Polpharma Biologics’ development program and underscore the company’s commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines